LYTIX — Lytix Biopharma AS Balance Sheet
0.000.00%
- NOK353.07m
- NOK224.91m
- NOK11.13m
Annual balance sheet for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | PRESS | ARS |
Standards: | NAS | NAS | IFRS | NAS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 28.4 | 197 | 145 | 50.5 | 131 |
Net Total Receivables | 4.17 | 5.68 | 6.74 | 12.8 | 13.1 |
Total Other Current Assets | |||||
Total Current Assets | 32.6 | 203 | 152 | 63.3 | 144 |
Net Property, Plant And Equipment | — | 2.14 | 1.38 | 0.11 | 2.63 |
Other Long Term Assets | |||||
Total Assets | 32.6 | 205 | 153 | 63.4 | 147 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12.7 | 14.2 | 17.8 | 12.1 | 36.8 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.7 | 15.5 | 18.2 | 12.1 | 38.6 |
Common Stock | |||||
Additional Paid In Capital | |||||
Other Equity | |||||
Total Equity | 19.9 | 190 | 135 | 51.4 | 108 |
Total Liabilities & Shareholders' Equity | 32.6 | 205 | 153 | 63.4 | 147 |
Total Common Shares Outstanding |